Main content
Eighth Celebration of Technology and Innovation honors entrepreneurs

Media Contact

Holly Korschun

The Office of Technology Transfer honors entrepreneurs and their innovations at the Eighth Annual Celebration of Technology and Innovation on Thursday, March 6 at at 4:30 p.m at the Emory Conference Center, Silver Bell Pavillion. To attend, RSVP to Ashley Myers at, 404-727-1785.

The 2014 winners are:

Start-up of 2013: Neurotrack

Stuart Zola, PhD

Stuart Zola

Dennis Liotta, PhD

Dennis Liotta

Martin Moore, PhD

Martin Moore

Stuart Zola, PhD, and Cecelia Manzanares (Yerkes)
Eugene Agichtein, PhD, and Dmitry Lagun, MS (math & computer science)

Neurotrack is an early-stage company that has developed computer-based tools for memory testing and behavioral assessment. The tools identify those at risk of Alzheimer’s disease or mild cognitive impairment well in advance of clinical disease diagnoses.

Deal of 2013: QUE Oncology

Dennis Liotta, PhD and Jim Snyder, PhD (chemistry)
Hyunsuk Shim, PhD (radiology)
Mary Galinski, PhD (infectious diseases & global health)

QUE Oncology, headquartered in Atlanta, is focused on the development of drugs to treat cancer and its consequences. As a joint venture between Emory University and UniQuest (Queensland, Australia), QUE Oncology has licensed two technologies from Emory, one that targets prostate cancer and one that targets breast cancer risk and hot flashes associated with estrogen hormone therapy.

Innovation of 2013: RSV Vaccine Technology

Martin Moore, PhD (pediatrics)

RSV (respiratory syncytial virus) is a major cause of lower respiratory tract infections in infants, children and the elderly. Vaccine development has been challenging and currently no RSV vaccine exists. Dr. Moore and his colleagues have used an alternative strategy to develop a vaccine focused on mutating certain genes of the virus to create a stable, live-attenuated RSV strain. This new recombinant RSV strain serves as a promising vaccine candidate currently being tested against RSV.

Keynote Speaker: Christopher Yochim

Christopher Yochim is director of external relations of Global Product and Portfolio Strategy for AstraZeneca. Yochim has global responsibility to drive awareness of AstraZeneca’s areas of partnering interest, with the goal of establishing AstraZeneca as a preferred partner within the biotechnology sector, venture capital and academic community. Through global integration, AstraZeneca has established a leading edge capability in licensing, mergers & acquisition, and strategic collaboration. Yochim has 19 years experience conducting technology transfer and academic relations at the North America Headquarters in Wilmington, Delaware.

He is a founding member and chairman of the Board of the Delaware Bioscience Association. He is a former member of the Executive Committee of the Board of Trustees of the Association of University Technology Managers (AUTM) and served as vice president for the Eastern US Region (2006-2007). Locally, he currently serves on the Board of Directors of PABio and The Japan America Society of Greater Philadelphia.

Following undergraduate education at Loyola University in New Orleans, Yochim graduated from Millsaps College in Jackson Miss. He joined the cardio-renal pharmacology department of ICI/Zeneca Pharmaceuticals in 1980. During 15 years in drug discovery research, he contributed to the development of numerous marketed therapeutic products, including treatments for high blood pressure, asthma and schizophrenia.

Emory Office of Technology Transfer (OTT)

The Emory OTT maintains a robust product pipeline, with one of the nation’s leading programs for guiding technology developed in the laboratory through the patenting and licensing process to the marketplace and into the hands of consumers and patients.

Emory currently manages more than 1,000 technologies invented by its scientists and physicians. This has led to the formation of 69 new companies and the introduction of more than 37 new products to market, some of which, like the discovery of several HIV drugs, have had major health and societal impact. Royalties earned from sales of new products by Emory licensees have resulted in more than $806 million that has subsidized additional Emory scientific research and education.